Lineage Cell Therapeutics Inc

For the period ended Dec 31, 2023. Filed Mar 7, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 7, 2024

LCTX$1.08+5.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Signatures

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 7, 2024	LINEAGE CELL THERAPEUTICS, INC.
	By:	/s/ Brian M. Culley
		Brian M. Culley
		Chief Executive Officer

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

DEBORAH ANDREWS
Signature	Title	Date
/s/ Brian M. Culley	Chief Executive Officer and Director	March 7, 2024
BRIAN M. CULLEY	(Principal Executive Officer)
/s/ Jill Ann Howe	Chief Financial Officer	March 7, 2024
JILL ANN HOWE	(Principal Financial and Accounting Officer)
/s/ Deborah Andrews	Director	March 7, 2024
/s/ Dipti Amin	Director	March 7, 2024
DIPTI AMIN
/s/ Don M. Bailey	Director	March 7, 2024
DON M. BAILEY
/s/ Neal C. Bradsher	Director	March 7, 2024
NEAL C. BRADSHER
/s/ Alfred D. Kingsley	Director	March 7, 2024
ALFRED D. KINGSLEY
/s/ Anula Jayasuriya	Director	March 7, 2024
ANULA JAYASURIYA
/s/ Michael H. Mulroy	Director	March 7, 2024
MICHAEL H. MULROY
/s/ Angus C. Russell	Director	March 7, 2024
ANGUS C. RUSSELL

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.